OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Grivas on Frontline Treatment Options in Metastatic RCC

April 12th 2024

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Dr Ball on the Use of Luspatercept in MDS With Anemia

April 12th 2024

Somedeb Ball, MBBS, discusses the benefits of luspatercept for patients with anemia due to a myelodysplastic syndrome.

Dr Koo on Challenges With PSMA PET in Prostate Cancer

April 12th 2024

Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.

Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian Cancer

April 12th 2024

Gabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.

Dr Sekeres on Using MDS Risk-Stratification Systems in Clinical Practice

April 12th 2024

Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

April 12th 2024

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast Cancer

April 12th 2024

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Dr Gangat on the Evolution of JAK Inhibitors in Myelofibrosis

April 12th 2024

Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Cobain on Second- and Later-Line Treatment Options in HR+/HER2– Breast Cancer

April 12th 2024

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

Dr Kasi on the Use of ctDNA to Help Inform Adjuvant Treatment Decisions in CRC

April 12th 2024

Pashtoon Murtaza Kasi, MD, M.S on the potential of ctDNA to guide further adjuvant treatment decisions in CRC and other tumor types.

Dr Westin on Early Findings With Azenosertib in High-Grade Serous Ovarian Cancer

April 11th 2024

Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib in patients with high-grade serous ovarian cancer.

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

April 11th 2024

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Overman on Future Research Directions in GI Cancer

April 11th 2024

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Dr Efstathiou on the Evolution of Trimodal Therapy in MIBC

April 11th 2024

Jason Efstathiou, MD, DPhil, discusses the utility of trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Nassar on MMR Determination by IHC and NGS in CRC and Endometrial Cancer

April 11th 2024

Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.

Dr Park on the Initial Efficacy of Epacadostat Plus Preoperative Chemoradiation in Rectal Cancer

April 11th 2024

Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.

Dr Goetz on the Early Pharmacokinetic Data With Neoadjuvant (Z)-endoxifen in ER+/HER2– Breast Cancer

April 11th 2024

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

Dr Koo on the Clinical Utility of PSMA PET in Prostate Cancer

April 11th 2024

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

April 10th 2024

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Dr Usmani on the Optimal Role for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 10th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.